Previous 10 | Next 10 |
Image source: The Motley Fool. Natera (NASDAQ: NTRA) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading
Natera Inc. (NTRA) Q4 2019 Earnings Conference Call February 26, 2020 16:30 ET CompanyParticipants Michael Brophy - CFO Steve Chapman - CEO Solomon Moshkevich - GM, Oncology & Transplant Bob Schueren - COO Conference Call Participants Max Masucci - Canaccord Genuity ...
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an upda...
SAN CARLOS, Calif. , Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019 , after the market close on February 26, 2020...
SAN CARLOS, Calif. , Feb. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it has filed suit against CareDx for false advertising in the U.S. District Court for Delaware , alleging CareDx used false an...
Cell-free DNA testing services provider Natera ( NTRA -0.2% ) will collaborate with Cambridge, MA-based Elicio Therapeutics on a Phase 1/2 clinical trial evaluating the latter's therapeutic cancer vaccine candidate ELI-002 for the adjuvant treatment of patients with pancreatic ducta...
CAMBRIDGE , Mass. and SAN CARLOS, Calif. , Feb. 11, 2020 /PRNewswire/ -- Elicio Therapeutics , a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a prospective, ...
Signatera test used for patient selection and monitoring to accelerate molecular proof of concept Elicio Therapeutics , a next generation immuno-oncology company, and Natera , Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a pros...
SAN CARLOS, Calif. , Jan. 27, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent"). The complaint was filed in the U.S. District ...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...